Published in J Acquir Immune Defic Syndr on January 01, 1992
Serological diagnosis of HIV infection using oral fluid samples. Bull World Health Organ (1994) 1.49
Salivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine. The NIAID AIDS Vaccine Evaluation Group. Clin Diagn Lab Immunol (1996) 0.78
Making sense of serotonin toxicity reports, a comment on Chopra et Al. (World J Biol Psychiatry 2004, 5: 114-115). World J Biol Psychiatry (2004) 0.75
Antibody to human immunodeficiency virus type 1 (HIV-1) gp160 in mucosal specimens of asymptomatic HIV-1-infected volunteers parenterally immunized with an experimental recombinant HIV-1 IIIB gp160 vaccine. The National Institute of Allergy and Infectious Diseases-sponsored AIDS Vaccine Evaluation Group. Clin Diagn Lab Immunol (1997) 0.75
Nonphotochemical Transformations of Phytochrome in Vivo. Plant Physiol (1963) 11.50
Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med (1983) 10.09
Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med (1988) 9.21
The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science (1989) 7.90
Structure of replicating simian virus 40 deoxyribonucleic acid molecules. J Virol (1971) 6.74
Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med (1985) 6.46
NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. Ann Intern Med (1984) 6.45
Origin and direction of simian virus 40 deoxyribonucleic acid replication. J Virol (1972) 6.39
Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol (1989) 6.02
Dark Transformations of Phytochrome in vivo. II. Plant Physiol (1965) 5.62
Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol (1998) 5.31
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A (1999) 5.25
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med (1999) 4.81
Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc Natl Acad Sci U S A (1990) 4.80
Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med (1984) 4.73
Interleukin-2 therapy in patients with HIV infection. N Engl J Med (2009) 4.38
Cryptococcosis in the acquired immunodeficiency syndrome. Ann Intern Med (1985) 4.25
Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med (1995) 4.06
Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol (1997) 3.64
Re-emergence of HIV after stopping therapy. Nature (1999) 3.54
HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med (1997) 3.40
Intermediate in SV40 DNA chain growth. Nat New Biol (1972) 3.38
Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol (1986) 3.29
Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS. Science (1984) 3.20
Immunologic abnormalities in the acquired immunodeficiency syndrome. Annu Rev Immunol (1985) 3.19
Bacteremia due to Mycobacterium avium-intracellulare in the acquired immunodeficiency syndrome. Ann Intern Med (1983) 3.06
Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV. J Exp Med (2001) 3.05
Resolutions and identification of the core deoxynucleoproteins of the simian virus 40. Biochem Biophys Res Commun (1973) 2.90
Sequential protein synthesis following vaccinia virus infection. J Virol (1968) 2.89
Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med (1996) 2.86
Immunopathogenesis of the acquired immunodeficiency syndrome. Ann Intern Med (1985) 2.77
Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-1) associated with clinical exposures. A prospective evaluation. Ann Intern Med (1990) 2.75
NIH conference. The acquired immunodeficiency syndrome: an update. Ann Intern Med (1985) 2.68
Increasing viral burden in CD4+ T cells from patients with human immunodeficiency virus (HIV) infection reflects rapidly progressive immunosuppression and clinical disease. Ann Intern Med (1990) 2.65
Integrated proviral human immunodeficiency virus type 1 is present in CD4+ peripheral blood lymphocytes in healthy seropositive individuals. J Virol (1989) 2.62
Death in the AIDS patient: role of cytomegalovirus. N Engl J Med (1983) 2.61
Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J Infect Dis (1994) 2.60
Direct polyclonal activation of human B lymphocytes by the acquired immune deficiency syndrome virus. Science (1986) 2.57
Inhibition in the joining of DNA intermediates to growing simian virus 40 chains. J Virol (1973) 2.44
Intestinal infections in patients with the acquired immunodeficiency syndrome (AIDS). Etiology and response to therapy. Ann Intern Med (1988) 2.42
JC virus enhancer-promoter active in human brain cells. Science (1984) 2.36
Sequential formation of vaccinia virus proteins and viral deoxyribonucleic acid replication. J Virol (1967) 2.34
Diagnosis of Pneumocystis carinii pneumonia: improved detection in sputum with use of monoclonal antibodies. N Engl J Med (1988) 2.33
Lack of clinical utility of cytomegalovirus blood and urine cultures in patients with HIV infection. Ann Intern Med (1993) 2.32
Site-specific base substitution and deletion mutations that enhance or suppress transcription of the SV40 major late RNA. Cell (1982) 2.32
Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest (1983) 2.32
Parallel evolution of drug resistance in HIV: failure of nonsynonymous/synonymous substitution rate ratio to detect selection. Mol Biol Evol (1999) 2.32
Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients. Proc Natl Acad Sci U S A (2000) 2.20
Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial. JAMA (2000) 2.20
Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome. Am J Med (1985) 2.18
In vitro antigen-induced, antigen-specific antibody production in man. Specific and polyclonal components, kinetics, and cellular requirements. J Exp Med (1981) 2.15
Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood (2000) 2.15
HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy. Lancet (1999) 2.13
Tales of tails: regulation of telomere length and telomerase activity during lymphocyte development, differentiation, activation, and aging. Immunol Rev (1997) 2.13
Ophthalmic involvement in acquired immunodeficiency syndrome. Ophthalmology (1984) 2.12
Monocyte function in the acquired immune deficiency syndrome. Defective chemotaxis. J Clin Invest (1984) 2.10
Defective clonogenic potential of CD8+ T lymphocytes in patients with AIDS. Expansion in vivo of a nonclonogenic CD3+CD8+DR+CD25- T cell population. J Immunol (1990) 2.05
Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy. J Infect Dis (2000) 1.96
Simian virus 40 major late promoter: an upstream DNA sequence required for efficient in vitro transcription. Mol Cell Biol (1984) 1.94
Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease. J Infect Dis (2000) 1.91
Risk of nosocomial infection with human T-cell lymphotropic virus type III/lymphadenopathy-associated virus in a large cohort of intensively exposed health care workers. Ann Intern Med (1986) 1.89
Reversible cardiac dysfunction associated with interferon alfa therapy in AIDS patients with Kaposi's sarcoma. N Engl J Med (1989) 1.88
CD8+ T lymphocytes of patients with AIDS maintain normal broad cytolytic function despite the loss of human immunodeficiency virus-specific cytotoxicity. Proc Natl Acad Sci U S A (1990) 1.88
Kaposi's sarcoma causing pulmonary infiltrates and respiratory failure in the acquired immunodeficiency syndrome. Ann Intern Med (1985) 1.86
Antigen-induced in vitro antibody production in humans: a model for B cell activation and immunoregulation. Proc Natl Acad Sci U S A (1981) 1.80
Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection. Arch Intern Med (1998) 1.77
Effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine on serious cytomegalovirus disease in eight immunosuppressed homosexual men. Ann Intern Med (1986) 1.77
Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells. J Immunol (1987) 1.74
COMPOSITIONAL AND PHYSIOLOGICAL CHANGES ASSOCIATED WITH THE CHEMICAL DEFOLIATION OF COTTON. Plant Physiol (1952) 1.71
Metabolic properties of early and late vaccinia virus messenger ribonucleic acid. J Virol (1967) 1.70
Specific initiation site for simian virus 40 deoxyribonucleic acid replication. J Virol (1972) 1.66
Frequent detection of HIV-1-specific mRNAs in infected individuals suggests ongoing active viral expression in all stages of disease. AIDS Res Hum Retroviruses (1991) 1.62
Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected persons. J Infect Dis (2006) 1.60
Effect of combined clofazimine and ansamycin therapy on Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS. J Infect Dis (1987) 1.60
NIH conference. Pneumocystis pneumonia: from bench to clinic. Ann Intern Med (1989) 1.58
Admission of AIDS patients to a medical intensive care unit: causes and outcome. Crit Care Med (1989) 1.57
Biosynthesis and processing of human immunodeficiency virus type 1 envelope glycoproteins: effects of monensin on glycosylation and transport. J Virol (1989) 1.53
Simian virus 40 guanine-cytosine-rich sequences function as independent transcriptional control elements in vitro. Mol Cell Biol (1984) 1.52
Telomere length, telomerase activity, and replicative potential in HIV infection: analysis of CD4+ and CD8+ T cells from HIV-discordant monozygotic twins. J Exp Med (1997) 1.50
Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Clin Infect Dis (2000) 1.48
Prognostic factors and life expectancy of patients with acquired immunodeficiency syndrome and Pneumocystis carinii pneumonia. Am Rev Respir Dis (1987) 1.47
Unwinding of parental strands during simian virus 40 DNA replication. J Virol (1973) 1.43
The SV40 DNA template for transcription of late mRNA in viral nucleoprotein complexes. Cell (1977) 1.42
Nonspecific interstitial pneumonitis: a common cause of pulmonary disease in the acquired immunodeficiency syndrome. Ann Intern Med (1987) 1.41
Enhanced mucosal reactions in AIDS patients receiving oropharyngeal irradiation. Int J Radiat Oncol Biol Phys (1987) 1.40
Characterization of Simian virus 40 DNA component II during viral DNA replication. J Mol Biol (1973) 1.40
Biochemical changes in phytohemagglutinin stimulated human lymphocytes. Exp Cell Res (1966) 1.39
Human immunodeficiency virus disease: changing patterns of intraocular inflammation. Am J Ophthalmol (1998) 1.38
In vitro transcription initiation by purified RNA polymerase II within the adenovirus 2 major late promoter region. J Biol Chem (1984) 1.38
Impairment of neutrophil bactericidal capacity in patients with AIDS. J Infect Dis (1988) 1.38
Occurrence and properties of a chromatin-associated F1-histone phosphokinase in mitotic Chinese hamster cells. Biochemistry (1972) 1.38
Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA (1999) 1.38